Saba Capital Management, L.P. Acquires 2,022 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. bought 2,022 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were bought at an average price of $12.88 per share, for a total transaction of $26,043.36. Following the acquisition, the insider now directly owns 2,738,992 shares of the company’s stock, valued at approximately $35,278,216.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Thursday, April 18th, Saba Capital Management, L.P. bought 81,738 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average price of $12.80 per share, for a total transaction of $1,046,246.40.

Abrdn Life Sciences Investors Stock Performance

NYSE:HQL opened at $13.13 on Thursday. The stock’s 50 day moving average price is $13.53 and its two-hundred day moving average price is $13.10. Abrdn Life Sciences Investors has a 12-month low of $11.34 and a 12-month high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were paid a $0.39 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. The ex-dividend date was Wednesday, February 21st. This represents a $1.56 annualized dividend and a yield of 11.88%.

Institutional Trading of Abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently bought and sold shares of HQL. Allspring Global Investments Holdings LLC raised its stake in Abrdn Life Sciences Investors by 12.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 347,615 shares of the company’s stock valued at $4,335,000 after buying an additional 38,000 shares during the period. 180 Wealth Advisors LLC raised its stake in Abrdn Life Sciences Investors by 5.3% in the third quarter. 180 Wealth Advisors LLC now owns 114,724 shares of the company’s stock valued at $1,431,000 after buying an additional 5,725 shares during the period. Shaker Financial Services LLC raised its stake in Abrdn Life Sciences Investors by 2.1% in the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock valued at $830,000 after buying an additional 1,342 shares during the period. Private Advisor Group LLC grew its position in shares of Abrdn Life Sciences Investors by 78.9% in the third quarter. Private Advisor Group LLC now owns 35,046 shares of the company’s stock valued at $435,000 after purchasing an additional 15,459 shares during the last quarter. Finally, RPO LLC grew its position in shares of Abrdn Life Sciences Investors by 75.7% in the third quarter. RPO LLC now owns 327,042 shares of the company’s stock valued at $4,078,000 after purchasing an additional 140,942 shares during the last quarter. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.